Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer
Authors:
- 9 February 2019
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (7) , 842-847
Abstract
To compare the prognostic outcomes between first-generation antiandrogen (FGA) and novel androgen-receptor-axis-targeted agent (ARATA) as first-line therapy in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).Keywords
This publication has 16 references indexed in Scilit:
- Predictors of Time to Metastasis in Castration-resistant Prostate CancerUrology, 2016
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE TrialJournal of Clinical Oncology, 2016
- Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical managementWorld Journal of Urology, 2016
- Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockadeMolecular and Clinical Oncology, 2016
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus PanelEuropean Journal of Cancer, 2014
- Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling TimeJournal of Clinical Oncology, 2013
- An update on androgen deprivation therapy for prostate cancerEndocrine-Related Cancer, 2010
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008